ASX:SPL Starpharma (SPL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Starpharma Stock (ASX:SPL) Get Starpharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume351,391 shsAverage VolumeN/AMarket CapitalizationA$43.90 millionP/E RatioN/ADividend Yield9.30%Price TargetN/AConsensus RatingN/A Company Overview Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia. Read More Receive SPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPL Stock News HeadlinesStarpharma Secures $3.7 Million R&D Tax Incentive to Boost Biotechnology AdvancementsAugust 27, 2025 | tipranks.comStarpharma Reports Revenue Decline but Adjusted Growth Amid R&D InvestmentsAugust 26, 2025 | tipranks.comPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for your money than tariffs is unfolding behind the scenes... Tucked inside this overlooked directive is a plan set to be executed for the first time in in U.S. history. One Stansberry Research's Senior Partner says it's set to trigger a rare window for potentially explosive gains in ONE asset immediately. (Not AI or crypto). Wall Street insiders are already positioning themselves... and he insists you should, too, before it's too late.September 16 at 2:00 AM | Stansberry Research (Ad)Starpharma Releases 2025 Corporate Governance StatementAugust 26, 2025 | tipranks.comHealth Check: Pro Medicus banks the profits as customers go the ‘full stack’August 14, 2025 | msn.comStarpharma’s DEP® SN38 Shows Promising Cancer Treatment ResultsNovember 21, 2024 | markets.businessinsider.comStarpharma Holdings: Advancing Clinical Pathways and GrowthOctober 31, 2024 | markets.businessinsider.comStarpharma Director Increases Shareholding SignificantlyOctober 24, 2024 | markets.businessinsider.comSee More Headlines SPL Stock Analysis - Frequently Asked Questions How were Starpharma's earnings last quarter? Starpharma Holdings Limited (ASX:SPL) released its earnings results on Wednesday, February, 27th. The company reported ($0.02) earnings per share for the quarter. Starpharma had a negative net margin of 91.45% and a negative trailing twelve-month return on equity of 26.10%. What other stocks do shareholders of Starpharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Starpharma investors own include Starpharma (SPHRY), Allena Pharmaceuticals (ALNA), Aurora Cannabis (ACBFF), Ampliphi Biosciences (APHB), AstraZeneca (AZN), Arbutus Biopharma (ABUS) and AcelRx Pharmaceuticals (ACRX). Company Calendar Last Earnings2/27/2019Today9/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:SPL CIKN/A Webwww.starpharma.com Phone+61-3-85322700FaxN/AEmployees45Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$8.16 million Net Margins-91.45% Pretax MarginN/A Return on Equity-26.10% Return on Assets-11.48% Debt Debt-to-Equity Ratio12.55 Current Ratio4.94 Quick Ratio5.65 Sales & Book Value Annual SalesA$9.76 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.42 Book ValueA$0.07 per share Price / BookN/AMiscellaneous Outstanding Shares417,370,000Free FloatN/AMarket CapA$43.90 million OptionableNot Optionable Beta0.77 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (ASX:SPL) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Starpharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Starpharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
